Contrasting Endonovo Therapeutics (OTCMKTS:ENDV) & Apogee Therapeutics (NASDAQ:APGE)

Endonovo Therapeutics (OTCMKTS:ENDV) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Endonovo Therapeutics and Apogee Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endonovo Therapeutics	0	0	0	0	0.00
Apogee Therapeutics	1	1	8	0	2.70

Apogee Therapeutics has a consensus price target of $92.63, suggesting a potential upside of 65.85%. Given Apogee Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Apogee Therapeutics is more favorable than Endonovo Therapeutics.

Institutional and Insider Ownership

79.0% of Apogee Therapeutics shares are owned by institutional investors. 5.6% of Endonovo Therapeutics shares are owned by company insiders. Comparatively, 42.8% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Endonovo Therapeutics and Apogee Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	N/A	N/A	N/A
Apogee Therapeutics	N/A	-34.65%	-32.76%

Valuation & Earnings

This table compares Endonovo Therapeutics and Apogee Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endonovo Therapeutics	$10,000.00	12.07	-$2.80 million	N/A	N/A
Apogee Therapeutics	N/A	N/A	-$182.15 million	($4.13)	-13.52

Endonovo Therapeutics has higher revenue and earnings than Apogee Therapeutics.

Volatility and Risk

Endonovo Therapeutics has a beta of -1.37, indicating that its stock price is 237% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.

Summary

Apogee Therapeutics beats Endonovo Therapeutics on 6 of the 10 factors compared between the two stocks.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

About Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.